Filing Flows › Agios Pharmaceuticals (AGIO) › R&D spending
Agios Pharmaceuticals (AGIO) R&D spending by quarter
Agios Pharmaceuticals' R&D spending was $73.5M in Q3 2026 (third quarter 2026), -27% from Q2 2026. Over the last 7 quarters it ranged from $72.7M (Q1 2025) to $101M (Q2 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $73.5M | -27% | -15% |
| Q2 2026 | $101M | +24% | +10% |
| Q1 2026 | $81.1M | -8% | +12% |
| Q4 2025 | $88.1M | +1% | — |
| Q3 2025 | $86.8M | -6% | — |
| Q2 2025 | $91.9M | +26% | — |
| Q1 2025 | $72.7M | — | — |
Q3 2026 at a glance
Agios Pharmaceuticals, Q3 2026: revenue $55.4M (+330% year over year), operating margin -139.3%, net loss $65.0M, operating cash flow −$59.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is Agios Pharmaceuticals' R&D spending?
Agios Pharmaceuticals' R&D spending was $73.5M in Q3 2026 (third quarter 2026), -27% from Q2 2026.
How has Agios Pharmaceuticals' R&D spending changed?
Over the last 7 quarters it ranged from $72.7M (Q1 2025) to $101M (Q2 2026).